Statewide Trends in Medications for Opioid Use Disorder Utilization in Rhode Island, United States, 2017-2023.

IF 4.2 3区医学 Q1 SUBSTANCE ABUSE Journal of Addiction Medicine Pub Date : 2024-11-26 DOI:10.1097/ADM.0000000000001411

Leah C Shaw, Benjamin D Hallowell, Taylor Paiva, Christina T Schulz, Mackenzie Daly, Samantha K Borden, Jamieson Goulet, Elizabeth A Samuels, Magdalena Cerdá, Brandon D L Marshall

{"title":"Statewide Trends in Medications for Opioid Use Disorder Utilization in Rhode Island, United States, 2017-2023.","authors":"Leah C Shaw, Benjamin D Hallowell, Taylor Paiva, Christina T Schulz, Mackenzie Daly, Samantha K Borden, Jamieson Goulet, Elizabeth A Samuels, Magdalena Cerdá, Brandon D L Marshall","doi":"10.1097/ADM.0000000000001411","DOIUrl":null,"url":null,"abstract":"Background: Buprenorphine and methadone are US Food and Drug Administration-approved medications for opioid use disorder (MOUD). Although utilization of MOUD was increasing pre-COVID-19, it is not well understood how this trend shifted during and \"after\" the COVID-19 pandemic in Rhode Island. This analysis will consider the differential utilization of MOUD over time and by key demographic factors.Methods: We utilized two of Rhode Island's statewide databases to examine aggregate counts of dispensed buprenorphine and methadone from January 1, 2017, to December 31, 2023. Data were stratified by age group, sex assigned at birth, and race/ethnicity (where available). Counts were stratified into pre-COVID-19 (Q1 2017-Q1 2020), COVID-19 (Q2 2020-Q4 2022), and endemic COVID-19 (2023) eras. Averages and annualized percent change for each period were calculated to understand how utilization changed over time.Results: Before COVID-19, buprenorphine and methadone utilization were increasing annually. During COVID-19, utilization declined annually by 0.40% and 0.43%, respectively. In the endemic COVID-19 time period, buprenorphine and methadone utilization declined more rapidly at 2.59% and 1.77%, respectively. Declines were more dramatic for adults aged 18-34.Conclusions: We observed a decline in MOUD utilization during and after COVID-19 in Rhode Island, primarily driven by substantial decreases in MOUD use among the youngest group of adult residents. Interventions specifically tailored to youth, such as school-based or primary healthcare-based programs, may be particularly effective in engaging with youth in substance use disorder treatment.","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Addiction Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ADM.0000000000001411","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Buprenorphine and methadone are US Food and Drug Administration-approved medications for opioid use disorder (MOUD). Although utilization of MOUD was increasing pre-COVID-19, it is not well understood how this trend shifted during and "after" the COVID-19 pandemic in Rhode Island. This analysis will consider the differential utilization of MOUD over time and by key demographic factors.

Methods: We utilized two of Rhode Island's statewide databases to examine aggregate counts of dispensed buprenorphine and methadone from January 1, 2017, to December 31, 2023. Data were stratified by age group, sex assigned at birth, and race/ethnicity (where available). Counts were stratified into pre-COVID-19 (Q1 2017-Q1 2020), COVID-19 (Q2 2020-Q4 2022), and endemic COVID-19 (2023) eras. Averages and annualized percent change for each period were calculated to understand how utilization changed over time.

Results: Before COVID-19, buprenorphine and methadone utilization were increasing annually. During COVID-19, utilization declined annually by 0.40% and 0.43%, respectively. In the endemic COVID-19 time period, buprenorphine and methadone utilization declined more rapidly at 2.59% and 1.77%, respectively. Declines were more dramatic for adults aged 18-34.

Conclusions: We observed a decline in MOUD utilization during and after COVID-19 in Rhode Island, primarily driven by substantial decreases in MOUD use among the youngest group of adult residents. Interventions specifically tailored to youth, such as school-based or primary healthcare-based programs, may be particularly effective in engaging with youth in substance use disorder treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

美国罗德岛州 2017-2023 年阿片类药物使用障碍用药全州趋势。

背景：丁丙诺啡和美沙酮是美国食品和药物管理局批准的治疗阿片类药物使用障碍（MOUD）的药物。尽管在 COVID-19 之前，MOUD 的使用率在不断上升，但在 COVID-19 大流行期间和 "之后"，罗德岛州对这一趋势的变化还不甚了解。本分析将考虑随着时间的推移和主要人口因素对 MOUD 的不同使用情况：我们利用罗德岛州的两个全州数据库，对 2017 年 1 月 1 日至 2023 年 12 月 31 日期间发放的丁丙诺啡和美沙酮的总计数进行了研究。数据按年龄组、出生时性别和种族/人种（如有）进行了分层。计数分为 COVID-19 前（2017 年第一季度至 2020 年第一季度）、COVID-19（2020 年第二季度至 2022 年第四季度）和 COVID-19 流行期（2023 年）。计算每个时期的平均值和年化百分比变化，以了解使用率随时间的变化情况：结果：在 COVID-19 之前，丁丙诺啡和美沙酮的使用量每年都在增加。在 COVID-19 期间，使用率每年分别下降 0.40% 和 0.43%。在 COVID-19 流行期间，丁丙诺啡和美沙酮的使用量下降得更快，分别为 2.59% 和 1.77%。18-34 岁成年人的使用率下降幅度更大：我们观察到，在 COVID-19 期间和之后，罗德岛州的 MOUD 使用量有所下降，主要原因是最年轻的成年居民群体中 MOUD 使用量的大幅下降。专门针对青少年的干预措施，如基于学校或初级医疗保健的计划，可能对青少年参与药物使用障碍治疗特别有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Addiction Medicine 医学-药物滥用

CiteScore

6.10

自引率

9.10%

发文量

260

审稿时长

>12 weeks

期刊介绍： The mission of Journal of Addiction Medicine, the official peer-reviewed journal of the American Society of Addiction Medicine, is to promote excellence in the practice of addiction medicine and in clinical research as well as to support Addiction Medicine as a mainstream medical sub-specialty. Under the guidance of an esteemed Editorial Board, peer-reviewed articles published in the Journal focus on developments in addiction medicine as well as on treatment innovations and ethical, economic, forensic, and social topics including: •addiction and substance use in pregnancy •adolescent addiction and at-risk use •the drug-exposed neonate •pharmacology •all psychoactive substances relevant to addiction, including alcohol, nicotine, caffeine, marijuana, opioids, stimulants and other prescription and illicit substances •diagnosis •neuroimaging techniques •treatment of special populations •treatment, early intervention and prevention of alcohol and drug use disorders •methodological issues in addiction research •pain and addiction, prescription drug use disorder •co-occurring addiction, medical and psychiatric disorders •pathological gambling disorder, sexual and other behavioral addictions •pathophysiology of addiction •behavioral and pharmacological treatments •issues in graduate medical education •recovery •health services delivery •ethical, legal and liability issues in addiction medicine practice •drug testing •self- and mutual-help.